Semaglutide Weight Management and Cardiovascular Risk Reduction
GLP-1 RAS recommended as first line treatment for people with
T2D with established ASCVD or with multiple CV risk factors
Updated ADA/EASD diabetes treatment guidelines
Lifestyle management
Goal: Cardiorenal risk reduction in high-risk T2D patients (on top of CV SoC)
Goal: HbA1c and weight management
ASCVD or indicators of high risk
Glycaemic management
GLP-1 with proven CVD
benefit
OR
SGLT-2i with proven CVD benefit
Metformin OR combination therapy with adequate efficacy to reach and
maintain goals (intermediate - very high)
Very high: Semaglutide mentioned for glucose lowering efficacy
HF with documented HFrEF or HFPEF
CKD
SGLT-2i with proven HF benefit
Weight management
Set individualized weight
management goals
When choosing glucose-lowering therapies consider regimen with high efficacy
SGLT-2i with primary evidence
of reducing CKD progression
THEN
GLP-1 with proven CVD
benefit
Very high: Semaglutide mentioned for weight loss efficacy
If additional cardiorenal risk reduction or glycaemic lowering needed
If HbA1c above target, identify barriers to reach treatment goals
Sources: Adapted from: "Standards of Medical Care in Diabetes - 2022" Supplement 1, p.133; diabetes.org. American Diabetes Association & "Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association
(ADA) and the European Association for the Study of Diabetes (EASD)", Davies MJ. Et al, Diabetes Care 2022 (https://doi.org/10.2337/dci22-0034)
GLP-1 RA: Glucagon like peptide-1 receptor agonist; ADA: American Diabetes Association; EASD: European Association for the Study of Diabetes; T2D: Type 2 diabetes; CV: Cardio vascular; SoC: Standart of care; ASCVD: Atherosclerotic cardiovascular disease;
CVD: Cardiovascular disease; SGLT-2i: Sodium/glucose co-transporter-2 inhibitors; HF: Heart failure: HFrEF: Heart failure with reduced ejection fraction; HFPEF: Heart failure with preserved ejection fraction; CKD: Chronic kidney diseaseView entire presentation